On March 26, 2009, Roche completed its acquisition of Genentech pursuant to a short-form merger in which Genentech became a wholly owned member of the Roche Group. Roche had announced earlier in the day the successful completion of its tender offer, which expired on Wednesday, March 25. In connection with the merger, all remaining public shareholders will, subject to appraisal rights, receive $95.00 per share for their shares.

Genentech's common stock will no longer be traded on the New York Stock Exchange after Thursday, March 26.

Roche Contact Information
F. Hoffmann-La Roche Ltd
Investor Relations
CH-4070 Basel
Switzerland
+41-61-688-8880

MacKenzie Partners (Roche's Information Agent - for information related to exchange of Genentech shares)
(212) 929-5500
(800) 322-2885
genentech@mackenziepartners.com

In 2008, Genentech reinvested $2.8 billion, or 21 percent of operating revenues on a GAAP basis, into research and development. View our current pipeline.